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ABSTRACT
Near-infrared (NIR) fluorescent probes are ideal for in vivo imaging, because they
offer deeper tissue penetration by the light and lower background autofluorescence than
fluorophores that emit in the visible range. Q3STCy is a newly synthesized, NIR lightemitting probe that is activated by an enzyme commonly overexpressed in tumor cells,
human nicotinamide adenine dinucleotide (phosphate): quinone oxidoreductase isozyme
1, known as hNQO1 or DT-diaphorase. The purpose of this study is to compare the
sensitivity of detecting peritoneal ovarian cancer metastasis (POCM) with Q3STCy and
gGlu-HMRG, a green fluorescent probe, upon their surface application. In vitro uptake
of Q3STCy was significantly higher than that of gGlu-HMRG. Using a red fluorescence
protein (RFP)-labeled in vivo tumor model of POCM, the Q3STCy probe provided high
sensitivity (96.9%) but modest specificity (61.0%), most likely the result of albuminprobe interactions and non-specific activation in nearby altered but healthy cells. Three
types of kinetic maps based on maximum fluorescence signal (MF), wash-in rate (WIR),
and area under the curve (AUC) allowed for differentiation of the activated fluorescence
signal associated with POCM from the background signal of the small intestine, thereby
significantly improving the specificity of Q3STCy to 80%, 100%, and 100% for MF,
WIR, and AUC, as well yielding a moderate improvement in sensitivity (100% for all
approaches) that is comparable to that with gGlu-HMRG, but with the added advantages
of NIR fluorescence as the transduction modality. Such a new methodology has the
potential to afford identification of cancerous lesions deeper within tissue.

investigated as a tool capable of augmenting the human eye
so as to improve the success of oncologic resections.
There are several major categories of fluorescent
probes designed for imaging applications, but the primary
consideration is whether probe emission is ‘alwayson’ or ‘activatable’ in nature [1]. Always-on probes
for identification of target tissues have the advantage
of simplicity in their design and synthesis, but the
disadvantage of high background signal, with the latter

INTRODUCTION
The success of oncologic procedures, such as surgery,
depends on the rapid and accurate localization of cancers,
followed by their complete resection or ablation. Although
large tumors are visible to the unaided human eye, tiny
foci (< 2 to 3 mm) of cancer may be impossible to see.
Consequently, optical fluorescence-guided imaging is being
www.impactjournals.com/oncotarget
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leading to the requirement of considerable time to clear the
always-on probe from nearby healthy tissue so as to achieve
adequate target-to-background ratios (TBRs). On the other
hand, activatable probes have much lower background
signals, thereby greatly improving the TBR, but they must
exhibit rapid activation for their implementation to be
practical; this latter requirement is key to the future of nonsystemically delivered activatable probes [2]. A particularly
useful method of probe activation is related to up-regulated
enzymatic activities associated with cancers, and this area
of research has given rise to a new generation of enzymeactivatable optical probes [3].
Another category of optical imaging probes is that
based on the energy of excitation and emission of the probe
or its corresponding reporter, specifically, whether such
energies are within or outside of the visible range. Selection
of a given energy-range probe depends on the nature of the
task at hand. For cancerous lesions located on the surface of
tissues, use of visible light-based probes is very reasonable
and has the advantage of not necessarily requiring additional
equipment. However, for lesions at some depth from the
surface, near-infrared (NIR) energies are preferred, due
to their ability to offer deeper tissue penetration [1, 4, 5].
Depending on the dimensions and location of the cancerous
tissue, the detection of intraperitoneal lesions may be
achieved using green or NIR light-emitting probes. Green
light-emitting probes have several advantages over their
NIR light-emitting counterparts. For example, green lightemitting probes can usually be chemically designed to have
a higher quantum yield and be of smaller molecular weight,
with the latter being very important for guided surgery
approaches employing topical (non-systemic) application
of the probe. Additionally, green light-emitting probes can
be seen with the naked eye. However, green light-emitting
probes have disadvantages, including high absorption of
light by tissue at the emission and excitation energies of the
probe, as well as the challenge of distinguishing background
tissue autofluorescence from fluorescence signal of the
probe, as a result of their spectral overlap. These factors
work to decrease the depth of tissue penetration and thereby
limit the achievable TBR. NIR light-emitting fluorescent
probes can visualize targets located deeper in tissues with
superior TBR, but their use requires NIR cameras for
visualization, as NIR-light is invisible to the naked eyes [4].
However, it is unclear whether there is an inherent
advantage to NIR probes compared to visible light for
tasks that might be required of an optical probe. In this
study, we compare the in vivo fluorescence cancer imaging
of a newly developed activatable NIR light-emitting
probe, Q3STCy, activated by human nicotinamide adenine
dinucleotide (phosphate): quinone oxidoreductase isozyme
1 (hNQO1) [6] with a previously described activatable
green light-emitting probe, gGlu-HMRG, whose
fluorescence is activated by γ-glutamyltranspeptidase
(GGT). The GGT-based probe has previously been
demonstrated to be capable of highly sensitive detection of
peritoneal ovarian cancer metastases (POCM) in an animal
www.impactjournals.com/oncotarget

model [7]. hNQO1 is a predominantly cytosolic enzyme
that uses NADH or NADPH equally well as cofactors
to specifically reduce quinones to hydroquinones [8].
The specific two-electron reduction of quinones to their
hydroquinone form by hNQO1 is historically considered
to be a detoxification mechanism, because this reaction
bypasses the formation of the highly reactive semiquinone
[9]. As a result, hNQO1 provides cells with multiple
layers of protection against oxidative stress, including
the direct detoxification of highly reactive quinones; the
maintenance of lipid-soluble antioxidants in their reduced
forms; and stabilization of the tumor suppressor p53 [10].
Chronic inflammation suppresses hNQO1 expression and
may increase susceptibility to cell injury. Paradoxically,
increasing evidence suggests that high expression levels of
hNQO1 at the early stages of carcinogenesis may provide
cancer cells with a growth advantage [11–13]. hNQO1 has
also been reported to be overexpressed 2- to 50-fold in
the cytosol of numerous human tumor cells (e.g., colon,
breast, pancreas, lung, and ovary) [9, 14, 15]. Therefore,
the Q3STCy probe has potential for aiding in the detection
of tiny cancer foci, such as intraperitoneal metastases.
Herein, we compared Q3STCy, a NIR light-emitting
probe activated by hNQO1, with gGlu-HMRG, a green
light-emitting probe activated by GGT, to detect POCM
in mice.

RESULTS
Synthesis and analysis of probe Q3STCy
Synthesis
The intermediate compound was first synthesized
through coupling the quinone propionic acid to the linker
2-mercaptoethanol, based on a previously published method
[16]. The resulting intermediate compound was then reacted
with 14 equivalents of phosgene in anhydrous THF for
12 h at room temperature. After the remaining, unreacted
phosgene was removed in vacuo, the crude product was
dissolved in THF, and this was injected into a solution
of TCy, which was first treated with sodium hydride in
anhydrous THF for 20 min. After reaction overnight and
vacuum removal of solvent, the final product Q3STCy
was obtained using flashing column with methanol in
dichloromethane as eluent. ESI-HRMS for [C52H64N3O5S]+:
842.4565 (observed); 842.4567 (calculated); 0.2 ppm error.
1
H-NMR and 13C-NMR spectra are in the Supplementary
Information, and they demonstrate the expected structural
characteristics of Q3STCy.
Mechanism of activation
The fluorescence of Q3STCy is revealed by hNQO1
due to cleavage of the fluorescence quenching quinone
propionic acid group upon its reduction by hNQO1 in the
presence of NADH cofactor and subsequent self-cleavage
of the 2-mercaptoethanol linker (Figure 1).
61182
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In vitro fluorescence imaging

with fluorescence of gGlu-HMRG and Q3STCy were
confirmed to be mostly coincident with RFP-positive foci.
However, Q3STCy fluorescence was also detected on the
surface of intra-abdominal organs, in particular the small
bowel (Figure 3A). The side-by-side mesenteric images of
the RFP-transfected SHIN3 animal models demonstrated
that the fluorescence of Q3STCy and gGlu-HMRG were
also mostly coincident with RFP-positive foci (Figure
3B), with fluorescence signal from the small bowel
being most pronounced in the Q3STCy images. Using
these images, the sensitivity and specificity of Q3STCy
and gGlu-HMRG were calculated. 124 foci exhibited
Q3STCy fluorescence among the 128 RFP-positive foci
(96.9% sensitivity), while 46 foci possessed a fluorescence
intensity > 6 a.u. among the 118 RFP-negative foci (61.0%
specificity). 100 foci displayed gGlu-HMRG fluorescence
above the threshold among the 103 RFP-positive foci
(97.1% sensitivity), while two foci showed gGlu-HMRG
fluorescence > 11 a.u. among the 84 RFP-negative foci
(97.6% specificity) (Figure 3C).
From the Q3STCy unmixed image, a fluorescence
intensity of 73.18 ± 82.95 a.u. and 13.48 ± 33.71 a.u. were

SHIN3 cells showed weak activation and
accumulation of Q3STCy or gGlu-HMRG probe after 10
min of incubation but strong activation and accumulation
beyond 1 h incubation, as confirmed by fluorescence
microscopy and flow cytometry (Figure 2). After 3 h
incubation with Q3STCy, SHIN3 cells exhibited much
more intense fluorescence compared to those incubated
with gGlu-HMRG for the same amount of time. The
relative MFI of Q3STCy was also significantly higher
compared to that of gGlu-HMRG, regardless of incubation
time (p < 0.01 for all incubation times) (Figure 2C).

In vivo activatable imaging
In vivo imaging demonstrated that SHIN3-DsRed
cells exposed to either Q3STCy or gGlu-HMRG exhibited
distinct fluorescence signals that could be distinguished
from the RFP fluorescence of SHIN3-DsRed cells. No
detectable signals were observed in control animals that
were not exposed to Q3STCy or gGlu-HMRG. After
intraperitoneal injection of probes, the signals associated

Figure 1: Chemical structure and their absorption and emission profiles of non-activated and activated Q3STCy
(Q3STCy and TCy).
www.impactjournals.com/oncotarget
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found for cancer foci and noncancerous foci, respectively.
The fluorescence intensity of cancer foci was significantly
higher and statistically different than that of noncancerous
foci (p < 0.01). Based on the gGlu-HMRG unmixed
image, it was found that the fluorescence intensity was
152.68 ± 135.58 a.u. and 1.96 ± 2.92 a.u. for cancer foci
and noncancerous foci, respectively. Once again, the
fluorescence intensity of cancer foci was significantly higher
than that of noncancerous foci (p < 0.01) (Figure 3D).

(Figure 4A and Supplementary Video 1). Importantly, the
fluorescence intensity of the SHIN3 tumor exposed to the
Q3STCy probe was higher than that of small intestine at all
time points (p < 0.01 at 10 and 20 min, and p = 0.01 at 30,
40, 50, and 60 min after spraying the probe, respectively)
(Figure 4B).
Extracted SHIN3 tumors demonstrated an increase
in fluorescence over the first several minutes after spraying
of the gGlu-HMRG probe, followed by a relatively timeinvariant signal (p < 0.01 at all time points) (Figure 4A and
Supplementary Video 2). It was found the fluorescence
intensity of the small intestine increased slightly but not
significantly after application of the gGlu-HMRG (p =
0.54, 0.27, 0.15, 0.10, 0.07, and 0.08 at 10, 20, 30, 40,
50, and 60 min after spraying the probe, respectively).
The measured fluorescence intensity of the SHIN3 tumor
exposed to the gGlu-HMRG probe was higher than that of
small intestine up to 50 min but not at 60 min (p < 0.01
at 10 and 20 min, p = 0.01, 0.02, 0.03, and 0.08 at 30,
40, 50, and 60 min after spraying the probe, respectively)
(Figure 4B).
The MF, WIR, and AUC were determined to be
significantly higher in the tumor versus the small intestine

Ex vivo activatable imaging
The intensity of fluorescence for extracted SHIN3
tumors increased significantly immediately after spraying
the Q3STCy probe (p < 0.01 at all time points for probetreated tumor vs prior to treatment) and gradually
increased over the 60-min time period measured (Figure
4A and Supplementary Video 1). The fluorescence
intensity of the healthy small intestine also increased in a
statistically significant fashion upon its spray exposure to
the Q3STCy probe, with a slight increase thereafter, up to
60 min (p = 0.05 and 0.01 at 10 and 20 min, p < 0.01 at 30,
40, 50, and 60 min after spraying the probe, respectively)

Figure 2: (A) Fluorescence microscopy studies. SHIN3 cells were incubated with Q3STCy and gGlu-HMRG for 10 min, 1, and 3 h. With
3 h incubation of Q3STCy SHIN3 cells showed stronger fluorescence compared to those incubated with gGlu-HMRG. (B) Flow cytometric
analysis. One representative individual is shown. (C) Relative MFI of Q3STCy was significantly higher compared to that of gGlu-HMRG
regardless of incubation time. Data are shown as mean relative MFI ± SEM.
www.impactjournals.com/oncotarget
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when using the NIR probe (p = 0.03, 0.02 and 0.01 for
MF, WIR, and AUC, respectively). In addition, the MF,
WIR, and AUC were also significantly higher in the tumor
than the small intestine exposed to the gGlu-HMRG (p =
0.04, 0.02 and 0.02 for MF, WIR, and AUC, respectively)
(Figure 5A and Table 1). The sensitivity and specificity
of the Q3STCy probe, as determined by threshold values
for diagnosing tumors, was 100% and 80%, 100% and
100%, and 100% and 100%, for MF, WIR, and AUC,
respectively. The sensitivity and specificity of gGluHMRG based on threshold values was 100% and 75%,
100% and 100%, and 100% and 100%, for MF, WIR, and
AUC, respectively (Figure 5B).

When FBS was added to 25 μM Q3STCy, the fluorescence
increased gradually but not significantly (p = 0.30,
0.13, 0.08, 0.06, 0.06, and 0.06 at 10, 20, 30, 40, 50,
and 60 min after adding Q3STCy, respectively) (Figure
4C). This increase in fluorescence is due to unfolding
of the quenched Q3STCy probe, not interferent-induced
activation/removal of the quinone group of the probe,
as verified by mass spectrometry inspection of such
solutions (Supplementary Information). Thus, the probe
is not activated by the presence of FBS, but rather its
~820-nm emission is increased, most likely the result of
decreased PeT quenching between the Q3 functionality
and the Cy group.

Dequenching of Q3STCy fluorescence

DISCUSSION

Q3STCy exhibited minimal fluorescence intensity
before adding FBS. However, after adding FBS to 100
μM Q3STCy, the fluorescence increased up to 60 min (p
= 0.01 at 10 min, < 0.01 at 20, 30, 40, 50, and 60 min).

The in vitro study using SHIN3 cells in monolayer
culture demonstrated weak activation of Q3STCy and
gGlu-HMRG probe and intracellular accumulation of
their respective reporters after a 10-min incubation, but

Figure 3: (A) Side-by-side images of RFP-transfected SHIN3 tumor-bearing mice injected i.p. with Q3STCy or gGlu-HMRG. The

fluorescence signals of RFP (red), Q3STCy (light blue), and gGlu-HMRG (yellow green) were unmixed with their spectral library. (B)
Side-by-side images of extracted mesenteries of with RFP-transfected SHIN3 foci and previously injected Q3STCy or gGlu-HMRG.
Fluorescence signals of RFP (red) and Q3STCy (light blue), or gGlu-HMRG (yellow green) are mostly coincident. However, fluorescence
signal of Q3STCy was also detected on surface of intraabdominal organ especially the small bowel. (C) Scatter plot of the fluorescence
intensities in each nodule. When RFP was used as a reference for location of SHIN3 cells, the sensitivity and specificity of detecting
SHIN3-RFP tumors were 96.9 and 61.0% for Q3STCy, and 97.1 and 97.6% for gGlu-HMRG, respectively. (D) Fluorescence intensity of
cancer foci and noncancerous foci on the Q3STCy and gGlu-HMRG unmixed images.
www.impactjournals.com/oncotarget
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Table 1: Three parameters calculated from subtracted dynamic images
Tumor

Small intestine

P value

MF

224.8 (81.2)

109.5 (92.1)

0.03

WIR

136.7 (64.9)

50.8 (34.1)

0.02

AUC

11004.5 (4352.0)

5073.4 (3454.8)

0.01

MF

131.1 (66.1)

70.9 (72.3)

0.04

WIR

67.6 (7.1)

12.5 (6.0)

0.02

AUC

4809.1 (3947.1)

1905.0 (2112.1)

0.0

Q3STCy

gGlu-HMRG

Data are the median (range).

Figure 4: (A) Time fluorescence intensity curve of the tumor and small intestine after spraying Q3STCy and gGlu-HMRG. Difference at each time

point compared to starting value was examined. (B) Time fluorescence intensity curve of the tumor and small intestine after spraying Q3STCy and gGluHMRG. Difference between tumor and small intestine was examined at each time point. (C) Time fluorescence intensity curve of Q3STCy after adding
FBS. Difference at each time point compared to starting value was examined.

www.impactjournals.com/oncotarget
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strong activation and accumulation was observed when the
SHIN3 cells were exposed to the probes for times greater
than 1 h, especially in the case of Q3STCy. In addition,
the relative MFI found for Q3STCy was significantly
higher compared to that of gGlu-HMRG, regardless of
incubation time (10 min, 1 and 3 h). Thus, we conclude
that Q3STCy is a promising activatable NIR probe for
detecting POCM, with its capabilities being comparable
to the previously established, excellent activatable probe,
gGlu-HMRG.
Q3STCy demonstrated very high sensitivity for
POCM. However, fluorescence was also detected on the
surface of intraabdominal organs, especially the small
bowel. This greatly reduced the specificity of the agent
(61.0%) in the abdomen, a significant concern, as POCM
are often found in association with the small bowel.
These results revealed that Q3STCy can detect POCM
with very high sensitivity, but modest specificity, most
likely the result of probe activation in nearby healthy
cells possessing higher-than-normal hNQO1 activity that
results from their being stimulated by products released
from their cancer cell neighbors [13, 17, 18]. Despite
this limitation, activation of Q3STCy by cancer foci was
significantly higher than by noncancerous tissue.

To further augment the capabilities of the new NIR
probe so as to identify tumor-specific fluorescence signal,
we employed kinetic parameters of the time-dependent
activated Q3STCy fluorescence signal to distinguish
cancerous and noncancerous tissue [19]. Ex vivo
activatable imaging showed that the fluorescence intensity
of SHIN3 tumors exposed to the NIR probe was higher
and developed more rapidly than that of small intestine
tissue exposed to the Q3STCy probe at all time points.
Moreover, the MF, WIR, and AUC kinetic parameters with
Q3STCy were significantly higher in tumors versus small
intestine tissue. Using WIR and AUC as the criteria, the
sensitivity and specificity based on the threshold values for
diagnosing tumors was determined to be 100 and 100%.
Thus, with these findings in hand, we anticipated that
the non-specific background signal of Q3STCy in tissues
can be overcome by kinetic maps derived from dynamic
fluorescence imaging during in vivo studies of POCM.
gGlu-HMRG was used as a reference compound
in this study. It demonstrated very high sensitivity and
specificity for detecting POCM (97.1% and 97.6%,
respectively), without using kinetic maps. However,
such a green light-emitting probe has some potential
disadvantages in clinical situations, including light

Figure 5: (A) Kinetic maps (MF, WIR, and AUC maps). On kinetic maps using both Q3STCy and gGlu-HMRG tumor showed clearly
higher value compared to small intestine. (B) Three parameters derived from kinetic map of tumor and small intestine. Red value and line
indicate the threshold value.
www.impactjournals.com/oncotarget
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MATERIALS AND METHODS

absorption by tissue and background autofluorescence
[2]. One approach to reduce autofluorescence is to unmix
known autofluorescence spectra from the optical probe
spectra. Indeed, we performed ‘unmixing’ to reduce the
autofluorescence from small intestine. However, current
spectral imaging is time-consuming, as it requires at
least several seconds per frame; thus, this method is not
necessarily well matched to real-time imaging applied to
surgical or endoscopic procedures [1, 20]. gGlu-HMRG
has been reported to be able to detect intraperitoneal
metastases in preclinical mouse models rapidly (within
10 min) because of its rapid and strong activation
upon contact with GGT on the surface of cancer cells;
however, concern has been expressed about the limited
penetration distance of green light in human-scaled
applications [7].
Fluorescent probes that absorb and emit
light in the NIR region are attractive because of
their low phototoxicity, and minimal absorption of
associated excitation/emission light by tissue and low
autofluorescence background due to the energy of the light.
As a result of these characteristics, NIR probes afford the
opportunity to detect biological events deep within tissues.
Indeed, autofluorescence from the small intestine did not
hamper the detection of activated Q3STCy fluorescence
signal from POCM, and such successful detection of
cancerous tissue did not require time-consuming spectral
unmixing. Moreover, tiny peritoneal tumors may hide in
the folded mesentery because it may be difficult to stretch
the whole mesentery and folded tissue is inevitable.
Q3STCy, a NIR light-emitting probe, may therefore, be
useful in such applications despite the need for a special
camera [4].
Genetic reporters have been reported to illuminate
cancer selectively in vivo [21–28]. However, ethical
considerations are needed clinically, because genetic
reporters require virus administration. In addition,
genetically engineered mouse models of cancer
reproduce the tumor microenvironment, including the
intact immune response, more accurately than human
cell line xenograft models [29, 30]. Yet, complicated
techniques are required to develop genetically engineered
mouse models. Thus, we chose a simple intraperitoneal
xenograft tumor model.
In conclusion, we describe a new activatable probe,
Q3STCy, whose hNQO1 activation leads to emission of
NIR light. Q3STCy showed high sensitivity but modest
specificity for detecting POCM. However, this modest
specificity could be overcome by creating kinetic maps.
The advantages of activatable NIR light-emitting probes
in POCM include deeper tissue penetration and less
background interference from autofluorescence. Thus,
we suggest that Q3STCy is a new alternative to existing
activatable probes for POCM which performs at very high
sensitivity and specificity when kinetic parameters are
considered.
www.impactjournals.com/oncotarget

Synthesis and analysis of probe Q3STCy
Q3STCy was synthesized as described previously
[6]. Quinone propionic acid [31] and the tricarbocyanine
fluorophore TCy [32] were synthesized using standard
procedures. All of the starting chemicals were purchased
from Sigma-Aldrich or Fisher Scientific and used as
received. Crude products were purified with 10-g silica
columns (Biotage) using methanol/dichloromethane
eluent. The Q3STCy probe was characterized by 1H-NMR,
13
C-NMR, and ESI-HRMS.

Cell lines and culture
The established ovarian cancer cell line, SHIN3
was used for in vitro fluorescence microscopy and flow
cytometry. SHIN3-DsRed, in which the red fluorescent
protein (RFP DsRed2)-expressing plasmid (Clontech
Laboratories, Mountain View, CA, USA) was previously
transfected, was used as the animal model of POCM
[33]. Cell lines were grown in RPMI 1640 supplemented
with 10% FBS and 1% penicillin-streptomycin (Life
Technologies) in tissue culture flasks in a humidified
incubator at 37°C in an atmosphere of 95% air and 5%
carbon dioxide.

In vitro fluorescence microscopy and
flow cytometry
To compare fluorescence intensities of Q3STCy
activated by hNQO1 and gGlu-HMRG activated by GGT,
we performed fluorescence microscopy with SHIN3
cells. 4 × 104 cells from each cell line were plated on a
culture well covered by a glass cover slip and incubated
in culture media for 24 h. Q3STCy or gGlu-HMRG (2
μM) was added to the culture medium and incubated for
10 min, 1, and 3 h. After incubation, cells were washed
once with phosphate-buffered saline solution (PBS), and
fluorescence microscopy was performed using an Olympus
BX61 microscope (Olympus America, Inc., Melville, NY)
equipped with the following filters: excitation wavelength
range 672.5–747.5 nm and emission wavelength range
765–855 nm for Q3STCy and excitation wavelength
range 450–490 nm and emission wavelength range 500–
550 nm for gGlu-HMRG. Transmitted light differential
interference contrast (DIC) images were obtained at the
same time.
For flow cytometry, 1 × 105 cells from each cell line
were plated in a 24-chamber culture well and incubated for
24 h. Q3STCy or gGlu-HMRG (2 μM) was added to the
culture medium, and cells were incubated for 10 min, 1,
and 3 h. A 488-nm argon ion laser was used for excitation.
Signals from cells were collected with a 515 to 545 nm
band-pass filter for gGlu-HMRG and a 653 to 669 nm
61188

Oncotarget

band-pass filter for Q3STCy. Cells were analyzed using
a FACS Calibur (BD BioSciences, San Jose, CA, USA).
Relative mean fluorescence intensity (MFI) was quantified
as the ratio MFItarget to MFIcontrol using CellQuest software
(BD BioScience). Samples were assayed three times in
duplicate.

and Q3STCy or gGlu-HMRG were then unmixed, based
on their spectral patterns, using commercial software
(Maestro software; CRi).
For image analysis of Q3STCy, regions of interest
(ROIs) were drawn within the tumor nodules depicted
by the RFP images (cancer foci: average fluorescence
intensity (AFI) ≧ 30 arbitrary units (a.u.)) and in the
surrounding adjacent areas (noncancerous foci: AFI < 30
a.u.), and then the average fluorescence intensity of each
ROI was calculated on the Q3STCy images with Maestro
software. The number of ROIs drawn in the noncancerous
areas was almost equal to the number drawn on cancer
foci (n = 123). All visible nodules with areas > 0.05 mm2
on RFP images were analyzed. Additional ROIs were
drawn on the nodules depicted on the Q3STCy images and
compared to the RFP images to validate the existence of
SHIN3 tumors. Positive signal for Q3STCy was defined as
an AFI greater than 6 a.u.; a negative signal was defined as
an AFI less than 6 a.u. The number of foci positive for both
Q3STCy and RFP, and positive only for either Q3STCy
or RFP was determined. The sensitivity of Q3STCy for
the detection of POCM was defined as the number of
peritoneal foci that were positive for both Q3STCy and
RFP divided by the total number of peritoneal foci positive
for RFP. Specificity of Q3STCy was defined as the number
of peritoneal foci negative for both RFP and Q3STCy
divided by the total number of peritoneal foci negative
for RFP.
Image analysis of gGlu-HMRG was performed in
exactly the same manner as that described for Q3STCy,
except that the threshold for RFP was 20 a.u. and for gGluHMRG was 11 a.u.
The difference in fluorescence intensity on the
Q3STCy or gGlu-HMRG images between cancer foci and
noncancerous foci was also determined.

Animal model
All procedures were performed in compliance with
the Guide for the Care and Use of Laboratory Animals
[34] and approved by the local Animal Care and Use
Committee in NCI/NIH. Six- to 8-week old female
homozygote athymic nude mice were purchased from
Charles River (National Cancer Institute, Frederick, MD).
Peritoneal metastases in nude mice were established
by intraperitoneal (i.p.) injection of 2 × 106 SHIN3-DsRed
cells suspended in 200 to 300 μl of PBS. Studies were
conducted 14–21 days after injection of the cells.
For an animal model of subcutaneous tumor, a
subcutaneous injection of 2 × 106 SHIN3 cells suspended
in 200 μl of PBS was performed in the right and left dorsi
of select mice. The mice were evaluated 7–10 days after
injection of the cells.

In vivo activatable imaging
To examine the sensitivity and specificity of
Q3STCy and gGlu-HMRG for imaging POCM, dilute
aqueous solutions of Q3STCy or gGlu-HMRG (300 μl
of 25 μM) were injected into the peritoneal cavities of
RFP-transfected SHIN3 tumor bearing mice (n ≧ 4 for
each group). Mice without injection of the probe under
investigation were also examined as controls. Mice were
euthanized with carbon dioxide 10 minutes after i.p.
injection of each probe. After euthanasia, the abdominal
walls were exposed, and mice were placed face up on a
nonfluorescent plate. Whole abdominal images, as well
as close-up images of the small bowel mesentery were
obtained. Subsequently, the small bowel mesentery
of each mouse was extracted and spread out on the
nonfluorescent plate. Spectral fluorescence images were
acquired using the Maestro In-Vivo Imaging System (Cri,
Woburn, MA, USA). The following filter set was used for
imaging RFP: a band-pass filter from 503 to 555 nm for
excitation and a long-pass filter for emitted light above
645 nm; for imaging Q3STCy: a band-pass filter from 710
to 760 nm for excitation light and a long-pass filter for
emitted light over 800 nm; and for imaging gGlu-HMRG:
a band-pass filter from 445 to 490 nm for excitation light
and a long-pass filter for emitted light over 515 nm. The
tunable emission filter was automatically stepped in 10
nm increments from 600 to 800 nm for RFP, from 700 to
900 nm for Q3STCy, and from 500 to 600 nm for gGluHMRG, at constant exposure. The spectral fluorescence
images consisting of spectra from autofluorescence, RFP,
www.impactjournals.com/oncotarget

Ex vivo activatable imaging
Kinetic maps derived from dynamic fluorescence
imaging have been reported to be useful for overcoming
the problem of dilution when using a sprayable
or surface-applied optical probe, such as the two
described here [19]. Thus, for differentiation between
the fluorescence signal arising from specific and nonspecific activation, we created kinetic maps using
extracted subcutaneous SHIN3 tumor and small bowel,
because the high fluorescence signal from the small
bowel often hampers the detection of intraperitoneal
metastases. Serial spectral fluorescence images were
acquired using the Maestro In-Vivo Imaging System
before and after spraying 10 μl of 100 μM Q3STCy
or gGlu-HMRG solution every 1 min, up to 60 min
after spraying the probes. The filter set and scanning
parameters used for Q3STCy and gGlu-HMRG were the
same as in the in vivo activatable imaging experiments.
The spectral fluorescence images, consisting of spectra
61189
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from autofluorescence, Q3STCy, or gGlu-HMRG were
then unmixed, based on their spectral patterns using
commercial software (Maestro software; CRi). Each
ROI was drawn either within the tumor nodule or
small intestine on the Q3STCy or gGlu-HMRG unmixed
image and average fluorescence signal intensity was
calculated.
Next, we calculated three previously reported
kinetic parameters—maximum fluorescence signal (MF),
wash-in rate (WIR), and area under the curve (AUC)—
and then created kinetic maps based on these three
parameters [19]. All images were analyzed using Image
J software (http://rsb.info.nih.gov/ij/). First, ROIs were
drawn on serial unmixed fluorescence dynamic images
within the tumor and in the normal small bowel, and then
the AFI of each ROI was calculated. Next, we generated
a fluorescence intensity curve using a time series of
images. Subtracted images were created by subtracting
the pre images (initial images before spraying the probe)
from each of the post images (images obtained after
spraying the probe). Then, we calculated the following
three parameters from each fluorescence intensity curve
using subtracted images: MF, WIR, and AUC. MF is the
maximum fluorescence signal observed during the entire
dynamic image set. WIR (fluorescence intensity/ min) is
the maximum slope approaching the MF. AUC is the area
measured under the time–fluorescence curve. Kinetic
maps based on these three parameters were created.
Finally, we defined a threshold value for each parameter
(152, 80, and 7000 for MF, WIR, and AUC with Q3STCy;
and 105, 30, and 3420 for MF, WIR, and AUC with gGluHMRG, respectively). Using these threshold values, we
calculated the sensitivity and specificity for diagnosing
the presence of a tumor.

relative MFI between Q3STCy and gGlu-HMRG was
determined with two-sided Mann–Whitney’s U test. We
performed receiver-operating characteristic analysis to
determine each threshold value. A two-sided Student’s ttest was used to compare the difference of fluorescence
intensity between cancer foci and noncancerous foci.
With respect to examining for non-specific activation of
Q3STCy in the ex vivo activatable imaging experiments,
we determined the differences in fluorescence intensity
every 10 min after spraying probe compared to the starting
value using Dunnett’s multiple comparison. The difference
in fluorescence intensity and three parameters calculated
from the subtracted dynamic images from tumor and
small intestine were examined with a two-sided Mann–
Whitney’s U test. Differences of p < 0.05 were considered
statistically significant.
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